GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Total Current Assets

Moderna (LIM:MRNA) Total Current Assets : $9,600 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Moderna's total current assets for the quarter that ended in Mar. 2024 was $9,600 Mil.


Moderna Total Current Assets Historical Data

The historical data trend for Moderna's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Total Current Assets Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 1,128.80 6,298.00 16,071.00 13,431.00 10,325.00

Moderna Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,122.00 10,599.00 10,799.00 10,325.00 9,600.00

Moderna Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Moderna's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Moderna's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Moderna  (LIM:MRNA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Moderna's Liquidation Value for the quarter that ended in Mar. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=8523-3912+0.75 * 137+0.5 * 295
=4,861

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna Total Current Assets Related Terms

Thank you for viewing the detailed overview of Moderna's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (LIM:MRNA) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LIM:MRNA) Headlines

From GuruFocus

Q3 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc ESG Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024